Image credit: iStock

Brief: GreenLight Biosciences agrees to go public in $1.2bn SPAC merger

August 10, 2021

Why it matters:

It’s the seventh agtech SPAC this year, as many sponsors set a target for environmentally beneficial tech companies. While GreenLight Biosciences has made a name for itself lately for its work on Covid-19 vaccines, it has its roots in agriculture, where it hopes to replace chemical pesticides.

Massachusetts-based GreenLight kills pests by targeting their RNA – the material that DNA employs to communicate what proteins to build – so they can’t manufacture essential proteins. Because GreenLight’s pesticide is so targeted, it only affects the intended organisms and does not impact the plant or surrounding environment, as many chemical pesticides do.

The company says it always intended to use its technology for human health too, and shifted focus to develop a Covid-19 vaccine when the pandemic hit in early 2020; it raised $102 million to this end last June.

Join the Newsletter

Get the latest news & research from AFN and AgFunder in your inbox.

Share on email
Share on twitter
Share on facebook
Share on linkedin
Share on reddit
Share on whatsapp
Share on skype
Join the Newsletter
Get the latest news and research from AFN & AgFunder in your inbox.

Follow us:


Sign up for our weekly food+ag+climate newsletter

This will close in 0 seconds

Join Newsletter